

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

**GRANT OF SHARE OPTIONS PURSUANT TO THE POST-IPO SHARE
OPTION SCHEME
AND
GRANT OF SHARE AWARDS PURSUANT TO THE POST-IPO SHARE
AWARD SCHEME**

The board of directors (the “**Board**”) of HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on 27 July 2022, the Company granted share options (the “**Share Options**”) and share awards (the “**Share Awards**”) to certain eligible participants under the share option scheme adopted by the shareholders of the Company on 23 November 2020 (the “**Share Option Scheme**”) and the share award scheme adopted by the shareholders of the Company on 23 November 2020 (the “**Share Award Scheme**”), respectively. A summary of the principal terms of the Share Option Scheme and the Share Award Scheme was set out in the Company’s prospectus dated 30 November 2020.

PURSUANT TO THE POST-IPO SHARE OPTION SCHEME

This section of the announcement is made pursuant to Rule 17.06A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

On 27 July 2022, the Company granted a total of 9,318,000 Share Options to subscribe for 9,318,000 ordinary shares in the Company (the “**Shares**”) to 22 eligible participants (collectively the “**Option Grantees**”) under the Share Option Scheme, subject to the acceptance of the Option Grantees. Details of the Share Options granted are as follows:

Date of grant : 27 July 2022
(the “**Grant Date**”)

Exercise price : HK\$6.20 per Share, save for the share options granted to two
(the “**Exercise Price**”) Option Grantees (who are not directors, chief executive or substantial shareholders of the Company) whose exercise price is HK\$5.65 per Share. The Exercise Price represents a premium over the highest of (i) the closing price of HK\$3.48 per Share as stated in the daily quotation sheets of the Stock Exchange on the Grant Date; (ii) the average closing price of HK\$3.53 per Share as stated in the Stock Exchange’s daily quotation sheets for the five consecutive trading days immediately preceding the Grant Date; and (iii) the nominal value of US\$0.000025 per Share.

- Vesting dates and validity period : (i) 25% of the Share Options will be vested on, and exercisable from, 31 March 2023;
- (ii) a further 25% of the Share Options will be vested on, and exercisable from, 31 March 2024;
- (iii) a further 25% of the Share Options will be vested on, and exercisable from, 31 March 2025; and
- (iv) the remaining 25% of the Share Options will be vested on, and exercisable from, 31 March 2026,

save for:

- (a) the Share Options granted to one Option Grantee (who is not a director, chief executive or substantial shareholder of the Company), of which (i) 25% will be vested on, and exercisable from, the Grant Date or the date on which the employee accepts the grant, whichever is later; (ii) a further 25% will be vested on, and exercisable from, 31 March 2023; (iii) a further 25% will be vested on, and exercisable from, 31 March 2024; and (iv) the remaining 25% will be vested on, and exercisable from, 31 March 2025; and
- (b) the Share Options granted to one Option Grantee (who is not a director, chief executive or substantial shareholder of the Company), of which (i) 25% will be vested on, and exercisable from, 11 April 2023; (ii) a further 25% will be vested on, and exercisable from, 11 April 2024; (iii) a further 25% will be vested on, and exercisable from, 11 April 2025; and (iv) the remaining 25% will be vested on, and exercisable from, 11 April 2026.

The Share Options have a term of 10 years from the Grant Date.

Among the total of 9,318,000 Share Options granted to the Option Grantees, 3,816,000 Share Options were granted to the following directors of the Company (“**Directors**”), subject to the acceptance of such Directors:

Name	Position	Number of Share Options granted
Dr. Jingsong Wang	Executive Director, chief executive officer and chairman of the Board of the Company	3,381,000
Dr. Yiping Rong	Executive Director	435,000

The grant of Share Options to the above Directors has been approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules. All the other Option Grantees are employees of the Group and are not a director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them. The grant of Share Options to such other Option Grantees has been approved by the chairman of the Board, namely Dr. Jingsong Wang, on the authority granted by the Board.

Reasons for and Benefits of the Grant of Share Options

The purposes of the grant of the Share Options and Share Awards are to retain high-calibre personnel, give incentive and reward to the grantees for their performance in the Company and to further align the interests of the Group with the respective grantees' interests and to create a shared stake in the Company's results.

GRANT OF SHARE AWARDS PURSUANT TO THE POST-IPO SHARE AWARD SCHEME

On a voluntary basis, on 27 July 2022, the Company announces that it granted a total of 3,381,000 Share Awards to 25 eligible participants (collectively, the "Share Award Grantees") under the Post-IPO Share Award Scheme, subject to the acceptance of the Share Award Grantees. Details of the Share Awards granted are as follows:

Date of grant (the "Share Award Grant Date") : 27 July 2022

Vesting dates and validity period : (i) 25% of the Share Awards will be vested on 31 March 2023;

(ii) a further 25% of the Share Awards will be vested on 31 March 2024;

(iii) a further 25% of the Share Awards will be vested on 31 March 2025; and

(iv) the remaining 25% of the Share Awards will be vested on 31 March 2026,

save for the Share Awards granted to three Share Award Grantees (who are not directors, chief executive or substantial shareholders of the Company), which will be vested in accordance with the schedule and other terms and conditions stipulated under their respective grant letters.

Among the total 3,381,000 Share Awards granted to the Share Award Grantees, 1,272,000 Share Awards were granted to the following Directors, subject to the acceptance of such Directors:

Name	Position	Number of Share Awards granted
Dr. Jingsong Wang	Executive Director, chief executive officer and chairman of the Board of the Company	1,127,000
Dr. Yiping Rong	Executive Director	145,000

The grant of Share Awards to the above Directors has been approved by the independent non-executive Directors. All the other Share Award Grantees are employees of the Group and are not a director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them. The grant of Share Awards to such other Share Award Grantees has been approved by the chairman of the Board, namely Dr. Jingsong Wang, on the authority granted by the Board.

By Order of the Board
HBM HOLDINGS LIMITED
Dr. Jingsong Wang
Chairman

Hong Kong, 27 July 2022

As of the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.